Jakub Swiercz

Company: Alesta Therapeutics

Job title: Vice President of Research & development

Seminars:

Tumour-like Conditions Enable the Development of Selective GCN2 Inhibitors 4:30 pm

Revealing nutrient deprivation in solid tumours, such as limited access to essential amino acids (AAs) in their microenvironment, which is crucial for understanding tumour metabolism and survival mechanisms in model systems Mimicking tumour-like conditions in preclinical models to identify vulnerabilities within the tumour microenvironment, enabling the discovery of novel therapeutic targets like GCN2 Developing GCN2…Read more

day: Conference Day One